Bio Protocol

• BIO Protocol funds and coordinates biotechnology research through decentralised science, or DeSci.

• It connects researchers, funders and communities to finance early-stage biotech that traditional funding overlooks.

• BIO is the network token.

• Genesis supply of 3.32 billion BIO, allocated 56% to the community including a 20% genesis auction and a 6% airdrop, 21.2% to core contributors, 13.6% to early backers and 4.2% to advisors.

• Used for funding allocation, governance and curating research proposals.

Pros:

• Early-stage biotech funding is a genuine gap, particularly for rare disease research.

• Intellectual property tokenisation gives contributors a claim on research outcomes.

• Backed by figures with credibility in both science and crypto.

Cons:

• Drug development timelines run a decade or more, far longer than crypto funding cycles tolerate.

• Regulatory approval processes cannot be accelerated by funding structure.

• Scientific outcomes are binary and most early-stage research fails.

• Exposure to decentralised science funding for biotechnology.

• The funding gap it targets is real.

• Weigh that biotech timelines and failure rates are fundamentally mismatched with token markets.

• Tokenised intellectual property claims on research outcomes, letting funders share in results rather than only donating.

• Early-stage biotech research, particularly for rare diseases, cannot attract conventional venture funding.

• Community funding fills the gap, though it cannot change how long or how often research fails.

• Backed by Binance Labs with involvement from researchers and DeSci community figures.

• Operates as a foundation coordinating multiple research DAOs.

• BIO held a public genesis auction in December 2024, selling 20% of supply and raising over $33 million, before listing on 3 January 2025 alongside a Binance Launchpool programme.

• Drug development timelines vastly exceed crypto market patience.

• Most early-stage research fails, and failure is total.

• Regulatory approval is outside the protocol's control.

• Intellectual property claims may prove difficult to enforce.